Hypercalcaemia, hypermagne-saemia, hyperphosphataemia and hyperaluminaemia in capd: Improvement in serum biochemistry by reduction in dialysate calcium and magnesium concentrations

Nephron

Volumn 72, Issue 1, 1996, Pages 52-58

  Hutchison, Alastair J ^a   Were, Anthony J ^a   Boulton, Helen F ^a   Mawer, E Barbara ^c   Laing, Ian ^b   Gokal, Ram ^a  

^a Renal Dialysis Unit   (United Kingdom)

^b MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Calcium carbonate; CAPD; Hypercalcaemia; Phosphate

Indexed keywords

ALUMINUM; ALUMINUM SALT; CALCIUM; CALCIUM SALT; COLECALCIFEROL; DIALYSIS FLUID; MAGNESIUM; PARATHYROID HORMONE; PHOSPHATE; PHOSPHATE BINDING AGENT;

ADULT; AGED; ARTICLE; BLOOD CHEMISTRY; CLINICAL ARTICLE; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; DIALYSATE; FEMALE; HEMODIALYSIS; HUMAN; HYPERCALCEMIA; HYPERMAGNESEMIA; HYPERPHOSPHATEMIA; MALE; PARATHYROID HORMONE BLOOD LEVEL; PRIORITY JOURNAL; SERUM;

ADULT; AGED; ALUMINUM; BICARBONATES; CALCIUM; FEMALE; HEMODIALYSIS SOLUTIONS; HUMANS; HYPERCALCEMIA; MAGNESIUM; MALE; MIDDLE AGED; PARATHYROID HORMONE; PERITONEAL DIALYSIS, CONTINUOUS AMBULATORY; PHOSPHATES;

EID: 0030068264     PISSN: 16608151     EISSN: 22353186     Source Type: Journal    
DOI: 10.1159/000188806     Document Type: Article

References (33)

1. Lopez-Hilker S. Galceran T, Chan U-L. Rapp N, Martin K, Slatopolsky H: Hypocalcaemia may not be essential for the development of secondary hyperparathyroidism in chronic renal failure. J Clin Invest 1986;78:1097-1102.
2. Lopez-Hilker S, Dusso A, Rapp N, Martin K, Slatopolsky E: Phosphorus restriction reverses hyperparathyroidism in uremia independent of changes in calcium and calcitriol. Am J Phvsiol 1990;259:432-437.
3. Ritz E, Matthias S. Seidel A. Reichel H. Szabo A, Horl W: Disturbed calcium metabolism in renal failure-Pathogenesis and therapeutic strategies. Kidney Int 1992;42(suppl 38):37-42.
4. Andreoli S, Bergstein J, Sherrard D: Aluminium intoxication from aluminium-containing phosphate binders in children with azotemia not undergoing dialysis. N Engl J Med 1984; 310:1079-1084.
5. Ackrill P. Day J, Ahmed R: Aluminium and iron overload in chronic dialysis. Kidney Int 1988;33(suppl 24):163-167.
6. de Broe M, D'Hasse P, Elseviers M. Clement J. Visser W. van de Vyver F: Aluminium and end-stage renal failure; in Davidson A (ed): Nephrology. Proc Xth ICN. Cambridge. Bal here Tindall. 1988, vol 2, pp 1086-1116.
7. Salusky I, Coburn J. Foley J. Nelson P. Fine R: Effects of oral calcium carbonate on control of serum phosphorus and changes in plasma aluminium levels after discontinuation of aluminium-containing gels in children receiving dialysis. J Pediatr 1986;108:767-770.
8. Slatopolsky E. Weerts C, Lopez-Hilker S. Norwood K, Zink M, Windus D, Delmez J: Calcium carbonate as a phosphate binder in patients with chronic renal failure undergoing dialysis. N Engl J Med 1986:315:157-161.
9. Stein H. Yudis M. Sirota R: Calcium carbonate as a phosphate binder. N Engl J Med 1987;316: 109-110.
10. Slatopolsky E, Weerts C, Norwood K. Giles K. Fryer P, Finch J. Windus D. Delmez J: Longterm effects of calcium carbonate and 2.5 mEq/ liter calcium dialysate on mineral metabolism. Kidney Int 1989;36:897-903.
11. Martis L, Serkes K, Nolph K: Calcium carbonate as a phosphate binder: Is there a need to adjust peritoneal calcium concentrations for patients using calcium carbonate? Périt Dial Int 1989;9:325-328.
12. Hutchison A. Frccmont A. Lumb G. Gokal R: Renal osteodystrophy in continuous ambulatory peritoneal dialysis; in Khanna R (ed): Advances in Peritoneal Dialysis. Toronto, University of Toronto Press. 1991, vol 7. pp 237-239.
13. Hutchison A, Freemont A, Boulton H, Gokal R: Low-calcium dialysis fluid and oral calcium carbonate in CAPD: A method of controlling hyperphosphataemia whilst minimizing aluminium exposure and hypercalcaemia. Nephrol Dial Transplant 1992;7:1219-1225.
14. Cunningham J, Beer J, Coldwcll R. Noonan K. Sawyer N. Makin H: Dialysate calcium reduction in CAPD patients treated with calcium carbonate and alfacalcidol. Nephrol Dial Transplant 1992;7:63-68.
15. Piraino B, Perlmutter J, Holley J, Johnston J, Bemardini J: The use of dialysate containing 2.5 mEq/1 calcium in peritoneal dialysis patients. Perit Dial Int 1992;12:75-76.
16. Hercz G. Pei Y, Manuel A. Saiphoo C, Goodman W, Segre G, Sherrard D: Aplastic osteodystrophy without aluminium staining in dialysis patients (abstract). Kidney Int 1990;37: 449.
17. Barsotti G, Lazzeri M, Cristofano C, Cerri M. Lupetti S, Giovannetti S: The role of metabolic acidosis in causing uremic hyperphosphatemia. Miner Electrolyte Metab 1986:12:103-106.
18. Payne R, Carver M, Morgan D: Interpretation of serum total calcium: Effects of adjustment for albumin concentration on frequency of abnormal values and on detection of change in the individual. J Clin Pathol 1979;32:56-60.
19. Mawer E, Hann J, Berry J, Davies M: Vitamin D metabolism in patients intoxicated with er-gocalciferol. Clin Sci 1985:68:135-141.
20. Mawer E. Berry J, Cundall J. Still P. White A: A sensitive radioimmunoassay that is equipo-tent for 1,25-dihydroxyvitamin Dj and D3. Clin Chim Acta 1990; 190:199-210.
21. Bowers G. Brassard C, Sena F: Measurement of ionized calcium in serum with ion-selective electrodes: A mature technology that can meet the daily service needs. Clin Chcm 1986:32: 1437-1447.
22. Morton A, Hercz G: Hypercalcaemia in dialysis patients: Comparison of diagnostic methods. Dial Transplant 1991;20:661-667.
23. Dunstan C, Evans R. Hills E. Wong S. Alfrey A: Effect of aluminium and parathyroid hormone on osteoblasts and bone mineralization in chronic renal failure. Calcif Tissue Int 1984:36: 133-138.
24. Borland Y, Charbit M. Henry J, Toga M. Cano J, Olmer M: Aluminum overload of parathyroid glands in haemodialyzed patients with hyperparathyroidism: Effect on bone remodelling. Nephrol Dial Transplant 1988:3:417-422.
25. Slatopolsky E. Lopez-Hilker S, Dusso A, Brown A, Morrissey J, Martin K: The interrelationship between vitamin D and parathyroid hormone secretion in health and disease; in Davidson A (ed): Nephrology. Proc Xth ICN. Cambridge, Ballierc Tindall, 1988, vol 2. pp 1067-1075.
26. Meric F, Yao P. Bia M: Etiology of hypercalcemia in hemodialysis patients on calcium carbonate therapy. Am J Kidney Dis 1990:16: 459-464.
27. Cohen Solal M, Sebcrt J, Boudailliez B, Marie A, Moriniere P, Gueris J, Bouillon R, Fournier A: Comparison of intact, midregion, and car-boxy-terminal assays of parathyroid hormone for the diagnosis of bone disease in hemodia-lyzed patients. J Clin Endocrinol Metab 1991; 73:516-524.
28. Hutchison A. Whitehouse R. Boulton H. Adams J. Mawer E, Freemont A, Gokal R: Correlation of bone histology with parathyroid hor mone, vitamin D, and radiology in end-stage renal disease. Kidney Int 1993:44:1071-1077
29. Fournier A, Moriniere P, Cohen Solal M, Boudailliez B. Achard J, Marie A, Sebert J: Adynamic bone disease in uremia: May it be idiopathic? Is it an actual disease? Nephron 1991; 58:1-12.
30. Gonella M, Ballanti P. Della Rocca C, Calabrese G, Pratesi G, Vagelli G, Mazzotta A, Bonucci E: Improved bone morphology by normalizing serum magnesium in chronically hc-modialyzed patients. Miner Electrolyte Metab 1988:14:240-245.
31. Breucr J, Moniz C, Baldwin D. Parsons V: The effects of zero magnesium dialysate and magnesium supplements on ionized calcium concentration in patients on regular dialysis treatment. Nephrol Dial Transplant 1987:2:347-350.
32. Mora Plama F, Ellis H, Cook D, Dewar J, Ware M, Wilkinson R, Kerr D: Osteomalacia in patients with chronic renal failure before dialysis or transplantation. Q J Med 1983:207: 332-348.
33. Lefebvre A, de Vemejoul M. Gueris J, Gold-farb B, Graulet A, Morieux C: Optimal correction of acidosis changes progression of dialysis osteodystrophy. Kidney Int 1989:36:1112-1118.